Speaking Engagement
Wednesday, February 4 at 3:45 P.M
Speaker: Taylor Jensen, VP, Head of Science Enterprise Oncology
Title: Leveraging ultrasensitive liquid biopsy solutions for longitudinal monitoring and treatment response in global testing
Summary
- Learn about clinically validated liquid biopsy CGP and MRD solutions developed to support global patient management clinical trials
- Explore the latest data demonstrating how parallel sequencing of plasma and buffy coat can filter CH variants for more accurate variant detection to enable monitoring and treatment response
- Review early updates on improved sensitivity of MRD applications for earlier detection of relapse, novel endpoints and precise treatment decision